GPU-based Deep Learning Enhances Drug Discovery Says Startup

By John Russell

May 26, 2016

Sifting the avalanche of life sciences (LS) data for insight is an interesting and important challenge. Many approaches are used with varying success. Recently, improved hardware – primarily GPU-based – and better neural networking schemes are bringing deep learning to the fore. Two recent papers report the use of deep neural networks is superior to typical machine learning (support vector machine model) in sieving LS data for drug discovery and personalized medicine purposes.

The two papers, admittedly driven by a commercial interest (Insilico Medicine), are nevertheless more evidence of deep neural network (DNN) progress in LS research where large datasets with high dimensionality have long been difficult to handle. Using DNN to train models and produce answers is proving quite effective; in these two studies both straightforward and more complicated neural network techniques were used. Snapshot:

Part of what’s interesting here is the broad applicability of the DNN approach. As the authors (listed below) note there are many in silico approaches to drug discovery and disease classification, including efforts to use transcriptional response to predict functional properties of drugs. Neural networks’ natural knack for handling high dimensional data is an important capability in LS. Deep learning has already proven very valuable in a range of activities spanning simple image recognition to physics applications.

Broadly, neural networks try to emulate the way biological neural networks operate. Artificial neural networks are generally presented as systems of interconnected “neurons” which exchange messages between each other. The connections have numeric weights that can be tuned based on experience, making neural nets adaptive to inputs and capable of learning. In essence they can be trained to understand and solve classes of problems.

For example, a neural network for handwriting recognition might be defined by a set of input neurons that are activated by the pixels of an input image. After being weighted and transformed by a function (determined by the network’s designer), the activations of these neurons are then passed on to other neurons. This process is repeated until finally, the output neuron that determines which character was read is activated.

The first study cited here relied on a standard multilayer perceptron (MLP), which is a feed forward artificial neural network model that maps sets of input data onto a set of appropriate outputs. In this instance, researchers worked with data from three cell lines (A549, MCF-7 and PC-3 cell lines from the LINCS project) that were treated with various compounds to elicit gene expression transcriptional profiles. Researchers began by classifying the compounds into therapeutic categories with DNN based solely on the transcriptional profiles. “After that we independently used both gene expression level data for “landmark genes” and pathway activation scores to train DNN classifier.” In total, the study analyzed 26,420 drug perturbation samples. Shown below is a representation of the DNN used in the drug study.

Study design: Gene expression data from LINCS Project was linked to 12 MeSH therapeutic use categories. DNN was trained separately on gene expression level data for “landmark genes” and pathway activation scores for significantly perturbed samples, forming an input layers of 977 and 271 neural nodes, respectively.
Study design: Gene expression data from LINCS Project was linked to 12 MeSH therapeutic use categories. DNN was trained separately on gene expression level data for “landmark genes” and pathway activation scores for significantly perturbed samples, forming an input layers of 977 and 271 neural nodes, respectively.

The details of the study are fascinating. Use of all the criteria was key to accuracy and the DNN effectiveness in coping with high dimensionality was a critical enabler.

In the second study, a more complicated ensemble approach proved most effective. Notably, this wasn’t a gene expression data analysis; rather it was based on blood-based markers. Data from roughly 60,000 blood samples from a single laboratory were analyzed. The five most predictive markers – albumin, glucose, alkaline phosphatase, urea, and erythrocytes – were identified. The best performing DNN achieved 81.5 percent accuracy, while the entire ensemble had 83.5 percent accuracy. The paper suggests the ensemble approach is likely most effective for integration of multimodal data and tracking of integrated biomarkers for aging.

DevBox_3qrtrOpen_wMonitorBoth studies required substantial compute power including the parallel processing capability of GPUs. NVIDIA assisted by providing early access to its DIGITS DevBox, which is a roughly 30Tflop deep learning machine featuring 4 Titan X GPU. “We also used a 2X Tesla K80 GPU system,” said Alex Zhavoronkov, an author on both papers and CEO of Insilico Medicine. “The original DNN in the molecular pharmaceutics [work] was trained on a Datalytics GPU cluster in New Mexico,” said Alex Zhavoronkov, CEO of Insilico Medicine and an author on both papers.

It bears repeating that Insilico Medicine was the main driver behind both papers and has a business interest in bolstering its credentials; that said, deep learning is a relatively small community where collaborations between academic, commercial, and technology suppliers are considerable. (For a snapshot of trends at the leading edge see HPCwire article, Beyond von Neumann, Neuromorphic Computing Steadily Advances.)

Insilico, founded in the 2014 timeframe, chose to focus on deep learning and signaling pathway activation analysis, which is an effective way to reduce dimensionality in gene expression data. “We are essentially a drug discovery engine now,” said Zhavoronkov, who has long been familiar with GPU technology having worked for several years at ATI Technologies. He’s also an ex-pat from Russia who has maintained close ties there; Insilico Medicine has grown to a staff of 39 including 22 in Moscow. Eleven are focused exclusively on deep learning.

Zhavoronkov divides the current deep learning community into three segments: one that is using off-the-shelf systems and tools; a second that is pushing the boundary and developing their own tools; and elite third components primarily focused on neural network R&D and developing new paradigms, citing Google DeepMind as one of the latter. “We fall into the middle category but also with domain expertise in drug discovery. There are few companies that have both.”

Perhaps predictably bullish, he said, “Both papers are first in class and demonstrate that deep learning can be very powerful in both drug discovery and biomarker development. In a short time we got over 800 strong hypotheses for both efficacy and toxicity of multiple drugs in many diseases.”

[i] Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data, Molecular Pharamaceutics, published by the American Chemical Society, http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00248; the manuscript is now posted on the “Just Accepted” service of the ACS. Authors listed: Alexander Aliper, Sergey Plis, Artem Artemov, Alvaro Ulloa, Polina Mamoshina, Alex Zhavoronkov

[ii] Deep biomarkers of human aging: Application of deep neural networks to biomarker development, published in the May issue of Aging (Vol 8, No5), http://www.impactaging.com/papers/v8/n5/full/100968.html. Authors listed: Evgeny Putin, Polina Mamoshina, Alexander Aliper, Mikhail Korzinkin, Alexey Moskalev, Alexey Kolosov, Alexander Ostrovskiy, Charles Cantor, Jan Vijg, and Alex Zhavoronkov

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

IDC: Will the Real Exascale Race Please Stand Up?

February 21, 2017

So the exascale race is on. And lots of organizations are in the pack. Government announcements from the US, China, India, Japan, and the EU indicate that they are working hard to make it happen – some sooner, some later. Read more…

By Bob Sorensen, IDC

ExxonMobil, NCSA, Cray Scale Reservoir Simulation to 700,000+ Processors

February 17, 2017

In a scaling breakthrough for oil and gas discovery, ExxonMobil geoscientists report they have harnessed the power of 717,000 processors – the equivalent of 22,000 32-processor computers – to run complex oil and gas reservoir simulation models. Read more…

By Doug Black

TSUBAME3.0 Points to Future HPE Pascal-NVLink-OPA Server

February 17, 2017

Since our initial coverage of the TSUBAME3.0 supercomputer yesterday, more details have come to light on this innovative project. Of particular interest is a new board design for NVLink-equipped Pascal P100 GPUs that will create another entrant to the space currently occupied by Nvidia's DGX-1 system, IBM's "Minsky" platform and the Supermicro SuperServer (1028GQ-TXR). Read more…

By Tiffany Trader

Tokyo Tech’s TSUBAME3.0 Will Be First HPE-SGI Super

February 16, 2017

In a press event Friday afternoon local time in Japan, Tokyo Institute of Technology (Tokyo Tech) announced its plans for the TSUBAME3.0 supercomputer, which will be Japan’s “fastest AI supercomputer,” Read more…

By Tiffany Trader

HPE Extreme Performance Solutions

O&G Companies Create Value with High Performance Remote Visualization

Today’s oil and gas (O&G) companies are striving to process datasets that have become not only tremendously large, but extremely complex. And the larger that data becomes, the harder it is to move and analyze it – particularly with a workforce that could be distributed between drilling sites, offshore rigs, and remote offices. Read more…

Drug Developers Use Google Cloud HPC in the Fight Against ALS

February 16, 2017

Within the haystack of a lethal disease such as ALS (amyotrophic lateral sclerosis / Lou Gehrig’s Disease) there exists, somewhere, the needle that will pierce this therapy-resistant affliction. Read more…

By Doug Black

Weekly Twitter Roundup (Feb. 16, 2017)

February 16, 2017

Here at HPCwire, we aim to keep the HPC community apprised of the most relevant and interesting news items that get tweeted throughout the week. Read more…

By Thomas Ayres

Alexander Named Dep. Dir. of Brookhaven Computational Initiative

February 15, 2017

Francis Alexander, a physicist with extensive management and leadership experience in computational science research, has been named Deputy Director of the Computational Science Initiative at the U.S. Read more…

Here’s What a Neural Net Looks Like On the Inside

February 15, 2017

Ever wonder what the inside of a machine learning model looks like? Today Graphcore released fascinating images that show how the computational graph concept maps to a new graph processor and graph programming framework it’s creating. Read more…

By Alex Woodie

IDC: Will the Real Exascale Race Please Stand Up?

February 21, 2017

So the exascale race is on. And lots of organizations are in the pack. Government announcements from the US, China, India, Japan, and the EU indicate that they are working hard to make it happen – some sooner, some later. Read more…

By Bob Sorensen, IDC

TSUBAME3.0 Points to Future HPE Pascal-NVLink-OPA Server

February 17, 2017

Since our initial coverage of the TSUBAME3.0 supercomputer yesterday, more details have come to light on this innovative project. Of particular interest is a new board design for NVLink-equipped Pascal P100 GPUs that will create another entrant to the space currently occupied by Nvidia's DGX-1 system, IBM's "Minsky" platform and the Supermicro SuperServer (1028GQ-TXR). Read more…

By Tiffany Trader

Tokyo Tech’s TSUBAME3.0 Will Be First HPE-SGI Super

February 16, 2017

In a press event Friday afternoon local time in Japan, Tokyo Institute of Technology (Tokyo Tech) announced its plans for the TSUBAME3.0 supercomputer, which will be Japan’s “fastest AI supercomputer,” Read more…

By Tiffany Trader

Drug Developers Use Google Cloud HPC in the Fight Against ALS

February 16, 2017

Within the haystack of a lethal disease such as ALS (amyotrophic lateral sclerosis / Lou Gehrig’s Disease) there exists, somewhere, the needle that will pierce this therapy-resistant affliction. Read more…

By Doug Black

Azure Edges AWS in Linpack Benchmark Study

February 15, 2017

The “when will clouds be ready for HPC” question has ebbed and flowed for years. Read more…

By John Russell

Is Liquid Cooling Ready to Go Mainstream?

February 13, 2017

Lost in the frenzy of SC16 was a substantial rise in the number of vendors showing server oriented liquid cooling technologies. Three decades ago liquid cooling was pretty much the exclusive realm of the Cray-2 and IBM mainframe class products. That’s changing. We are now seeing an emergence of x86 class server products with exotic plumbing technology ranging from Direct-to-Chip to servers and storage completely immersed in a dielectric fluid. Read more…

By Steve Campbell

Cray Posts Best-Ever Quarter, Visibility Still Limited

February 10, 2017

On its Wednesday earnings call, Cray announced the largest revenue quarter in the company’s history and the second-highest revenue year. Read more…

By Tiffany Trader

HPC Cloud Startup Launches ‘App Store’ for HPC Workflows

February 9, 2017

“Civilization advances by extending the number of important operations which we can perform without thinking about them,” Read more…

By Tiffany Trader

For IBM/OpenPOWER: Success in 2017 = (Volume) Sales

January 11, 2017

To a large degree IBM and the OpenPOWER Foundation have done what they said they would – assembling a substantial and growing ecosystem and bringing Power-based products to market, all in about three years. Read more…

By John Russell

US, China Vie for Supercomputing Supremacy

November 14, 2016

The 48th edition of the TOP500 list is fresh off the presses and while there is no new number one system, as previously teased by China, there are a number of notable entrants from the US and around the world and significant trends to report on. Read more…

By Tiffany Trader

Lighting up Aurora: Behind the Scenes at the Creation of the DOE’s Upcoming 200 Petaflops Supercomputer

December 1, 2016

In April 2015, U.S. Department of Energy Undersecretary Franklin Orr announced that Intel would be the prime contractor for Aurora: Read more…

By Jan Rowell

D-Wave SC16 Update: What’s Bo Ewald Saying These Days

November 18, 2016

Tucked in a back section of the SC16 exhibit hall, quantum computing pioneer D-Wave has been talking up its new 2000-qubit processor announced in September. Forget for a moment the criticism sometimes aimed at D-Wave. This small Canadian company has sold several machines including, for example, ones to Lockheed and NASA, and has worked with Google on mapping machine learning problems to quantum computing. In July Los Alamos National Laboratory took possession of a 1000-quibit D-Wave 2X system that LANL ordered a year ago around the time of SC15. Read more…

By John Russell

Enlisting Deep Learning in the War on Cancer

December 7, 2016

Sometime in Q2 2017 the first ‘results’ of the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C) will become publicly available according to Rick Stevens. He leads one of three JDACS4C pilot projects pressing deep learning (DL) into service in the War on Cancer. Read more…

By John Russell

IBM Wants to be “Red Hat” of Deep Learning

January 26, 2017

IBM today announced the addition of TensorFlow and Chainer deep learning frameworks to its PowerAI suite of deep learning tools, which already includes popular offerings such as Caffe, Theano, and Torch. Read more…

By John Russell

HPC Startup Advances Auto-Parallelization’s Promise

January 23, 2017

The shift from single core to multicore hardware has made finding parallelism in codes more important than ever, but that hasn’t made the task of parallel programming any easier. Read more…

By Tiffany Trader

CPU Benchmarking: Haswell Versus POWER8

June 2, 2015

With OpenPOWER activity ramping up and IBM’s prominent role in the upcoming DOE machines Summit and Sierra, it’s a good time to look at how the IBM POWER CPU stacks up against the x86 Xeon Haswell CPU from Intel. Read more…

By Tiffany Trader

Leading Solution Providers

Nvidia Sees Bright Future for AI Supercomputing

November 23, 2016

Graphics chipmaker Nvidia made a strong showing at SC16 in Salt Lake City last week. Read more…

By Tiffany Trader

BioTeam’s Berman Charts 2017 HPC Trends in Life Sciences

January 4, 2017

Twenty years ago high performance computing was nearly absent from life sciences. Today it’s used throughout life sciences and biomedical research. Genomics and the data deluge from modern lab instruments are the main drivers, but so is the longer-term desire to perform predictive simulation in support of Precision Medicine (PM). There’s even a specialized life sciences supercomputer, ‘Anton’ from D.E. Shaw Research, and the Pittsburgh Supercomputing Center is standing up its second Anton 2 and actively soliciting project proposals. There’s a lot going on. Read more…

By John Russell

Tokyo Tech’s TSUBAME3.0 Will Be First HPE-SGI Super

February 16, 2017

In a press event Friday afternoon local time in Japan, Tokyo Institute of Technology (Tokyo Tech) announced its plans for the TSUBAME3.0 supercomputer, which will be Japan’s “fastest AI supercomputer,” Read more…

By Tiffany Trader

IDG to Be Bought by Chinese Investors; IDC to Spin Out HPC Group

January 19, 2017

US-based publishing and investment firm International Data Group, Inc. (IDG) will be acquired by a pair of Chinese investors, China Oceanwide Holdings Group Co., Ltd. Read more…

By Tiffany Trader

Dell Knights Landing Machine Sets New STAC Records

November 2, 2016

The Securities Technology Analysis Center, commonly known as STAC, has released a new report characterizing the performance of the Knight Landing-based Dell PowerEdge C6320p server on the STAC-A2 benchmarking suite, widely used by the financial services industry to test and evaluate computing platforms. The Dell machine has set new records for both the baseline Greeks benchmark and the large Greeks benchmark. Read more…

By Tiffany Trader

What Knights Landing Is Not

June 18, 2016

As we get ready to launch the newest member of the Intel Xeon Phi family, code named Knights Landing, it is natural that there be some questions and potentially some confusion. Read more…

By James Reinders, Intel

KNUPATH Hermosa-based Commercial Boards Expected in Q1 2017

December 15, 2016

Last June tech start-up KnuEdge emerged from stealth mode to begin spreading the word about its new processor and fabric technology that’s been roughly a decade in the making. Read more…

By John Russell

Intel and Trump Announce $7B for Fab 42 Targeting 7nm

February 8, 2017

In what may be an attempt by President Trump to reset his turbulent relationship with the high tech industry, he and Intel CEO Brian Krzanich today announced plans to invest more than $7 billion to complete Fab 42. Read more…

By John Russell

  • arrow
  • Click Here for More Headlines
  • arrow
Share This